Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | RARB | P10826 | 3/20 | 0.55 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17830938 | 1.00 | CYP2D6 (0.56) | CYP2D6CYP3A4RARBNR5A1CYP19A1 | |
| SCHEMBL25557802 | 0.98 | RARB (0.58) | CYP2D6CYP3A4RARBNR5A1CYP19A1 | |
| SCHEMBL7855901 | 0.94 | NR5A1 (0.58) | NR5A1LTA4HHRH3KDM4ETP53 | |
| SCHEMBL8727734 | 0.93 | NR5A1 (0.61) | RARBNR5A1LTA4HHRH3KDM4E | |
| SCHEMBL12762363 | 0.93 | NR5A1 (0.61) | RARBNR5A1LTA4HHRH3KDM4E | |
| SCHEMBL23266158 | 0.93 | NR5A1 (0.61) | RARBNR5A1LTA4HHRH3KDM4E | |
| SCHEMBL12251286 | 0.93 | NR5A1 (0.61) | RARBNR5A1LTA4HHRH3KDM4E | |
| SCHEMBL13216578 | 0.93 | NR5A1 (0.61) | RARBNR5A1LTA4HHRH3KDM4E | |
| SCHEMBL9593021 | 0.91 | HRH3 (0.57) | CYP2D6CYP3A4NR5A1LTA4HHRH3 | |
| SCHEMBL22248702 | 0.87 | HRH3 (0.62) | CYP3A4HRH3KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902148-B2 | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent | THERAVANCE, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20090221470-A1 | USE OF AN ECHINOCANDIN ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT | CUMBERLAND PHARMACEUTICALS INC. | 2009-09-03 | — | — | US | disclosed |
| US-7452861-B2 | Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent | THERAVANCE, INC. (US) | 2008-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221470-A1 | USE OF AN ECHINOCANDIN ANTIFUNGAL AGENT IN COMBINATION WITH A GLYCOPEPTIDE ANTIBACTERIAL AGENT | DPM1, ERG28, ENGASE | CYP2D6 1295/4885CYP3A4 1968/4885RARB 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.